Non-alcoholic Steatohepatitis Clinical Trials Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Non-alcoholic Steatohepatitis Clinical Trials Market, By Study Design
7.1. Non-alcoholic Steatohepatitis Clinical Trials Market, by Study Design, 2021-2030
7.1.1. Interventional
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Observational
7.1.2.1. Market Revenue and Forecast (2019-2030)
7.1.3. Expanded Access
7.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Non-alcoholic Steatohepatitis Clinical Trials Market, By Phase
8.1. Non-alcoholic Steatohepatitis Clinical Trials Market, by Phase, 2021-2030
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Non-alcoholic Steatohepatitis Clinical Trials Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.1.2. Market Revenue and Forecast, by Phase (2019-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.1.3.2. Market Revenue and Forecast, by Phase (2019-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.1.4.2. Market Revenue and Forecast, by Phase (2019-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.2.2. Market Revenue and Forecast, by Phase (2019-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.2.3.2. Market Revenue and Forecast, by Phase (2019-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.2.4.2. Market Revenue and Forecast, by Phase (2019-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.2.5.2. Market Revenue and Forecast, by Phase (2019-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.2.6.2. Market Revenue and Forecast, by Phase (2019-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.3.2. Market Revenue and Forecast, by Phase (2019-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.3.3.2. Market Revenue and Forecast, by Phase (2019-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.3.4.2. Market Revenue and Forecast, by Phase (2019-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.3.5.2. Market Revenue and Forecast, by Phase (2019-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.3.6.2. Market Revenue and Forecast, by Phase (2019-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.4.2. Market Revenue and Forecast, by Phase (2019-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.4.3.2. Market Revenue and Forecast, by Phase (2019-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.4.4.2. Market Revenue and Forecast, by Phase (2019-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.4.5.2. Market Revenue and Forecast, by Phase (2019-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.4.6.2. Market Revenue and Forecast, by Phase (2019-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.5.2. Market Revenue and Forecast, by Phase (2019-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.5.3.2. Market Revenue and Forecast, by Phase (2019-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Study Design (2019-2030)
9.5.4.2. Market Revenue and Forecast, by Phase (2019-2030)
Chapter 10. Company Profiles
10.1. Pfizer Inc.
10.1.1. Company Overview
10.1.2. Study Design Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Novartis AG
10.2.1. Company Overview
10.2.2. Study Design Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Icon Plc
10.3.1. Company Overview
10.3.2. Study Design Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. LabCorp
10.4.1. Company Overview
10.4.2. Study Design Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Allergan Plc
10.5.1. Company Overview
10.5.2. Study Design Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Cadila Healthcare Ltd.
10.6.1. Company Overview
10.6.2. Study Design Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Shire Plc (Takeda Pharmaceuticals)
10.7.1. Company Overview
10.7.2. Study Design Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Eli Lilly
10.8.1. Company Overview
10.8.2. Study Design Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Novo Nordisk
10.9.1. Company Overview
10.9.2. Study Design Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Gilead Sciences Inc.
10.10.1. Company Overview
10.10.2. Study Design Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
Glossary of Terms